Molecular discordance between brain metastases and primary lung tumors: A Retrospective Study - 18/11/26
, Rayan Fawaz a, c, Mathilde Fouet a, François Léopold Maison a, Bogdan Ene a, Yordanka Yordanova a, Jean Marc Delmas a, Hélène Barrazutti b, Christophe Joubert a, cHighlights |
• | PD-L1, EGFR and KRAS were compared in paired lung tumors and brain metastases. |
• | PD-L1 discordance occurred in 4 of 14 evaluable pairs (28.6%). |
• | PD-L1 loss and gain occurred in both directions at similar rates. |
• | EGFR and KRAS were concordant in most pairs, but pairs were few. |
• | Molecular reassessment may help when brain tissue is already available. |
ABSTRACT |
Introduction |
Brain metastases (BM) occur in 40–50% of patients with lung cancer, and management relies partly on PD-L1, EGFR and KRAS status. Molecular discordance between primary tumors and BM may affect systemic therapy. We evaluated molecular discordance between primary lung tumors and BM.
Methods |
In this retrospective single-center study (Percy Military Hospital, 2015–2024), adults with histologically confirmed lung cancer and BM on MRI were included. The primary endpoint was the molecular profile (PD-L1, with TPS ≥ 1% considered positive; EGFR; KRAS) of paired primary tumors and BM, analyzed in evaluable pairs only. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan–Meier method from BM diagnosis.
Results |
Of 59 patients, 18 had samples from both sites, and PD-L1 was evaluable at both sites in 14. PD-L1 discordance occurred in 4 of 14 pairs (28.6%): loss in 3 of 9 PD-L1-positive and gain in 1 of 5 PD-L1-negative primary tumors. EGFR and KRAS were discordant in 1 of 16 and 1 of 10 evaluable pairs, respectively. Median OS was 24 months (95% CI 15–56) and median PFS 7 months (95% CI 5–8), without difference between synchronous and metachronous presentations.
Conclusion |
PD-L1 discordance was frequent and occurred in both directions at similar rates, without evidence of systematic loss in BM. Given the few evaluable pairs, these findings are exploratory, and the stability of EGFR and KRAS status cannot be concluded. Molecular reassessment may be informative when BM tissue is already available for clinical reasons; these data do not support systematic brain biopsy.
Le texte complet de cet article est disponible en PDF.Keywords : primary lung cancer, brain metastasis, molecular profiling, molecular discordance
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
